Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049192 · ClinicalTrials.gov registry record · Phase 2
Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00049192: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00049192 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 43 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00049192, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Phase II trial to study the effectiveness of combining oblimersen with imatinib mesylate in treating patients who have chronic myelogenous leukemia that has not responded to previous treatment with imatinib mesylate. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Oblimersen may help imatinib mesylate kill more cancer cells by making cancer cells more sensitive to the drug.
Interventions
- OTHER laboratory biomarker analysis
- DRUG imatinib mesylate
- BIOLOGICAL oblimersen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2002-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049192
The ClinicalTrials.gov registry entry for NCT00049192 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00049192 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049192 about?
NCT00049192 is a clinical study titled "Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia". Phase II trial to study the effectiveness of combining oblimersen with imatinib mesylate in treating patients who have chronic myelogenous leukemia that has not responded to previous treatment with imatinib mesylate. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes neces...
What is the current status of trial NCT00049192?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2002-11.
What interventions are being tested in trial NCT00049192?
The interventions under investigation include: laboratory biomarker analysis (OTHER), imatinib mesylate (DRUG), oblimersen sodium (BIOLOGICAL).
Who is sponsoring clinical trial NCT00049192?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.